Give each injection site at least a week of rest before returning to it
During the initial period of using any new transdermal medication, patients may experience local skin reactions such as mild redness, itching, or irritation at the application site
For instance, liposomal carriers have been developed to encapsulate exenatide and liraglutide, demonstrating improved stability and sustained release upon subcutaneous or intranasal administration
If proven safe and effective, these patches may offer a more convenient, less invasive option for people who use GLP-1 medications in the future.
As a cornerstone therapy for T2DM, GLP-1 receptor agonists (GLP-1RAs) have undergone continuous improvement, culminating in the development of "biased GLP-1RAs," with ecnoglutide serving as an example
These prices include the medication itself, physician review, injection supplies, and free shipping